Azenta, Inc.

NASDAQ:AZTA

Medical - Instruments & Supplies

Healthcare
$48.69 -0.11%

-$0.03 today

Market cap
$2.13B
Beta
1.40
P/E (TTM)
-5.9
EPS (TTM)
-$3.87
52W Low $15.93High $41.73

Volume 0.69M

Average 1.16M

AZTA Sales of Investments

Cash received from selling or redeeming investments.

Azenta, Inc.NASDAQ: AZTA

Sales of Investments · Q4 FY2026 · quarter ended Sep 2026

Sales of investments declines year over year

Q4 FY2026 sales of investments of $33.12M fell 77.5% year over year, behind the -16.8% change in trailing-twelve-month sales of investments. Sequentially, it rose 14.1% from the prior quarter. Over 3 fiscal years it compounded at -33.0% a year.

Context

  • Sales of investments amounted to 52.9% of revenue in FY2026, down 13.6 pp from a year earlier.
  • Sales of investments increased in 0 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -77.5% toward the trailing-twelve-month pace of -16.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$33.12M+14.1% QoQ
Last fiscal yearSep 2026
$328.61M-16.8% YoY
LTMSep 2026
$328.61M-16.8% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.5%——
1 year-16.8%——
3-year CAGR-33.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2026
328.61M USD
Year-over-year change
-16.8%
4-year CAGR
-17.4%

Sales of Investments vs competitors

How AZTA compares with its peers on the latest reported figures

  • AZTA's LTM Sep 2026 sales of investments of $328.61M is the 2nd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -16.8% is the 3rd highest of 7, against a peer median of -45.6%.
  • Sales of investments amounts to 52.9% of revenue for AZTA, versus a peer median of 0.2%.
AZTA Competitors Peer median
Sales of Investments for AZTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.56B -24.4%+370.8%3.3%
AZTAAzenta, Inc.LTM Sep 2026$328.61M -16.8%-33.0%52.9%
DHRDanaher CorporationLTM Sep 2026$233M +1564.3%-12.6%0.9%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$117.5M -110.4%-61.3%4.5%
BLFSBioLife Solutions, Inc.LTM Mar 2026$56.36M +211.2%+67.1%56.5%
TECHBio-Techne CorporationLTM Sep 2026$1.99M -66.8%-61.8%0.2%
SOLVSolventum CorporationLTM Jun 2026$0 ——0.0%
BRKRBruker CorporationLTM Jun 2026$0 -100.0%—0.0%
NEOGNeogen CorporationLTM Aug 2026$0 ——0.0%
MLABMesa Laboratories, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding AZTA) $0-45.6%-12.6%0.2%

Competitors are the stored peer set for AZTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Net Income2.13B(14.64M)(164.9M)(55.76M)(166.99M)
Depreciation & Amortization53.7M85.58M90.74M61.21M56.52M
Deferred Income Tax24.47M(28.74M)(15.89M)(27.04M)(5.17M)
Stock-Based Compensation10.67M9.38M14.47M20.88M12.24M
Change in Working Capital(72.73M)(29.04M)3.04M(22.84M)4.06M
Accounts Receivables(31.4M)34.46M(12.07M)(24.56M)4.42M
Inventory(66.63M)8.25M15.9M(2.67M)(8.04M)
Accounts Payables(3.93M)(14.71M)9.2M1.04M12.66M
Other Working Capital29.22M(57.04M)(9.99M)3.36M(4.99M)
Other Non-Cash Items(2.62B)(16.71M)122.28M95.73M156.84M
Operating Cash Flow(466.05M)5.83M49.74M72.18M57.51M
Capital Expenditures(77.44M)(39.44M)(37.39M)(33.86M)(30.08M)
Acquisitions (Net)2.81B(386.51M)00(11.15M)
Purchases of Investments(1.98B)(236.19M)(405.58M)(451.41M)(375.68M)
Sales of Investments705.38M1.09B667.71M394.81M328.61M
Other Investing Activities(4M)00054.5M
Investing Cash Flow1.47B431.38M224.74M(90.46M)(33.8M)
Debt Repayment(50.11M)(578K)(783K)(985K)(748K)
Common Stock Issued5.25M3.62M3.28M2.77M2.2M
Common Stock Repurchased0(838.51M)(661.7M)0(118.29M)
Dividends Paid(7.49M)0000
Other Financing Activities(10.4M)(4.99M)0(11.38M)(2.67M)
Financing Cash Flow(62.76M)(840.46M)(659.21M)(9.59M)(119.5M)
Effect of Forex Changes(180.82M)45.99M21.67M3.57M(2.58M)
Net Change in Cash755.96M(357.25M)(363.06M)(24.31M)(98.37M)
Free Cash Flow(543.48M)(33.6M)12.35M38.32M27.43M

Azenta, Inc.

NASDAQ:AZTA

Intrinsic Alpha fair value

Locked

Current Price

$48.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.